Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

MD Anderson and Takeda announce agreement to develop off-the-shelf CAR NK-cell therapy platform

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, for the treatment of B-cell malignancies and other cancers.

5 Nov 2019

Scientists harness the power of immune system to test novel cancer treatment

The field of immunotherapy has revolutionized the way people with incurable cancers are treated, saving the lives of many people whose disease would have otherwise been seen as a death sentence. Despite its success in treating people with deadly forms of leukemia and lymphoma, there are still many people who do not benefit from the treatment or eventually experience a relapse of their cancer.

16 Oct 2019

Novel cancer-driving mutation discovered in vast non-coding regions of the cancer genome

An Ontario-led research group has discovered a novel cancer-driving mutation in the vast non-coding regions of the human cancer genome, also known as the "dark matter" of human cancer DNA.

9 Oct 2019

Researchers discover metabolic vulnerability in cancer cells with mutated spliceosomes

A research team from the Johns Hopkins Kimmel Cancer Center reports it has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes.

From Johns Hopkins Medicine 3 Oct 2019

Leukemia is not just one disease

An estimated 61,780 new cases of leukemia will be diagnosed in the United States this year, with some 2,000 cases in New Jersey, according to the American Cancer Society.

30 Aug 2019

People who have a parent, sibling, or child with blood cancer have higher risk of disease

New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease.

9 Aug 2019

New leukemia treatment developed from common wild flower

Researchers have discovered how to turn a compound from a common wildflower called Feverfew into a new treatment for leukemia.

1 Aug 2019

New tool reveals how genes interact to form tissues and organisms

Although the knowledge we have about human cells and tissues has steadily increased over recent decades, many things remain unknown.

4 Jun 2019

Combination treatment effective as front-line therapy for select chronic lymphocytic leukemia patients

Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia, have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.

30 May 2019

Study identifies patterns of chronic lymphocytic leukemia growth

In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study.

29 May 2019

Researchers identify why lymphoma patients may become resistant to specific drug

With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern.

16 May 2019

New test could be a ‘game changer’ in the treatment of chronic lymphocytic leukemia

The first test to quickly and accurately predict how people will respond to standard treatment for the most common type of leukemia has been developed at Cardiff University. The technology could guide doctors’ decisions on which drugs to give to patients.

27 Feb 2019

EU-funded project investigates molecular mechanisms of aging in adult stem cells

Stem cells are the ultimate mother cells of the human body. Not only do they have the capacity to self-renew, they can develop into specific cell types as the body requires. But as the human body ages, the regenerative capacity of our stem cells diminishes.

8 Feb 2019

New approach identifies epigenetic changes in leukemia cells for patients undergoing ibrutinib treatment

Many new anti-cancer drugs inhibit proteins that are essential for the proliferation of cancer cells. One example is ibrutinib, an innovative therapy for chronic lymphocytic leukemia first approved in 2014.

29 Jan 2019

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

FDA approves new combination therapy for acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.

30 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Barcelona researchers win one of the most prestigious EU grants to study CLL

The European Research Council today announced the results of the 2018 Synergy Grants call for proposals. The aim of Synergy Grants is to address ambitious research questions that can only be answered by the coordinated work of a small group of two to four principal investigators and their teams, bringing together their complementary skills, knowledge and resources.

26 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018